CDKN2A negative

The negative conization rate was 11.9%, with diagnostic errors identified across pre-surgical biopsy, cone specimen, and deeper levels. Risk factors included older age, higher parity, low expression of p16, Ki-67 and geminin (p<0.05). Recurrence represented 8.1% of the negative cones, without identification of statistically significant risk factors. Pathological review with deeper level sections and 2-year follow-up are recommended for patients with negative conizations.

The verrucous (warty) SCC subtype case was HPV6-positive and p16-negative. The presence of HPV16 and p16 overexpression in the examined tissue specimens lends additional support for the role of HPV in the etiology of scrotal SCC.

There is strong correlation between EGFR overexpression and M2 polarization in patients with p16-negative OPC. Immunotherapy with or without EGFR inhibitor could be considered in these high-risk patients.

P2, N=60, Recruiting, IO Biotech | N=30 --> 60

P2, N=180, Not yet recruiting, ECOG-ACRIN Cancer Research Group | Initiation date: Jan 2024 --> Apr 2024

The large amount of ascites decreased after the start of administration of fulvestrant and CDK4/6 inhibitor(PAL). Fifty months later, she continues to do good ADL and PR status. We experienced a case of metastatic breast cancer with massive ascites and peritoneal metastasis that was successfully treated with a CDK4/6 inhibitor(PAL)and achieved long- term survival.

To conclude, the mean viral load in HPVDNA+/p16+ OPSCC was higher than in HPVDNA+/p16- OPSCC, but there was no statistically significant difference in viral load depending on OPSCC subsite or on clinical outcome.

SPINK5, a known tumour suppressor gene in HNSCC, was already downregulated in low-grade dysplastic lesions, indicating an early deactivation in the evolution of the disease. Genomic alterations as well as aberrant immune gene expression can be observed early on in the evolution of tumours of the upper aerodigestive tract, highlighting the potential for targeting early mechanisms of disease progression.

Our study revealed that CDKN2A LOF NSCLC patients treated with immune checkpoint inhibitor (ICI) mono-therapy or combined therapy had a worse prognosis than those with CDKN2A wild-type NSCLC. However, our study also suggested that ICI could work quite effectively in selective CDKN2A LOF patients.

In the patients with T3 & T4a EACSCC, prognosis of the patients with positive p16 expression EACSCC tended to be better than those with negative p16 expression. These results suggest the clinical significance of EGFR and p16 expressions in the patients with advanced EACSCC to predict oncological outcomes.

P2, N=30, Recruiting, IO Biotech | Trial completion date: Aug 2028 --> Jan 2027 | Trial primary completion date: Sep 2025 --> Apr 2025

1. Ours is the first study to demonstrate that SP263 and E3L1N can reliably be used to evaluate PD-L1 in PCs as there is good concordance with the reference clone 22C3. 2.

P2, N=45, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2025

P=N/A, N=420, Recruiting, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Trial completion date: Jan 2025 --> Jun 2025 | Trial primary completion date: Apr 2024 --> Sep 2024

The P value was not significant when p16 positivity with other parameters. HPV-associated were 90%, HPV-independent were 10%.

Tumor volume, p16, and CSC markers are potential biomarkers for HDF for patients with HNSCC treated with (C-)RT. Lower expression of CSC in p16+ OPSCC may contribute to better tumor control.

P1, N=42, Not yet recruiting, University of Chicago | Trial primary completion date: Nov 2025 --> Oct 2027

P2, N=97, Recruiting, University Medical Center Groningen | Not yet recruiting --> Recruiting

P2, N=0, Withdrawn, Replimune Inc. | N=130 --> 0 | Not yet recruiting --> Withdrawn

P=N/A, N=100, Completed, Tata Medical Center | Recruiting --> Completed | Phase classification: P1/2 --> PN/A

This analysis highlighted the value of singular p16 immunohistochemical absence as a predictor for aggressive biological behavior and unfavorable prognosis in familial melanoma and/or MPM, in comparison with the exclusive loss of p14, indifferent to the histopathological subtype. The present study emphasizes the utility of immunohistochemistry as a less expensive method of complementing the current testing arsenal and could represent the starting point for the elaboration of tailored diagnostic and therapeutic algorithms, based on the discovered p14-p16-CDKN2A significant correlation.

P1/2, N=96, Completed, Washington University School of Medicine | Active, not recruiting --> Completed | Trial completion date: Oct 2024 --> Nov 2023

Furthermore, wt (intact) CDKN2A/IFNA14 were found to be associated with longer survival in recurrent GBMs. Our data suggest that co-deletion of CDKN2A/IFNA14 in GBM negatively correlates with survival and CDKN2A-wt status correlated with longer survival, and with second surgery, itself a marker for improved patient outcomes.

P2, N=30, Recruiting, IO Biotech | Not yet recruiting --> Recruiting

P=N/A, N=177, Active, not recruiting, Medical University of South Carolina | Recruiting --> Active, not recruiting

Aberrant p53 and p16 immunostaining increases during grade and stage progression although p53 negative and p16 positive immunostaining lack prognostic significance in pT2-4 carcinomas. Potential diagnostic features are that high level p16 expression is limited to neoplastic urothelium and p53 null phenotype to aggressive cancers (grade 3 and invasive).

P1, N=33, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: Oct 2023 --> Oct 2024

The palbociclib, cetuximab and IMRT combination was well-tolerated. The RP2D was established, while no MTD was determined. The regimen demonstrated promising preliminary efficacy, suggesting further investigation is warranted in cisplatin-ineligible p16/HPV-unrelated LA-HNSCC patients.

The verification results with TCGA and LUAD patients' samples supported that the p16 Cgi shore is a key methylation regulatory region. Our findings suggested that methylation of the Cgi shore in the p16 non-promoter region can hamper the transcriptional activity of OTX2, leading to a reduction in the expression of p16, which might contribute to the development of lung cancer.

Four histologically different HPV-independent penile precursor lesions can be assigned to 2 major genetic/biological pathways with characteristic highly differentiated precursors requiring different clinical management decisions. These include d-PeIN in chronic inflammatory dermatoses, with p53 overexpression and TP53/CDKN2A mutations, and the p53 wild-type verrucous and verruciform precursors unassociated with dermatoses, but with mutations in oncogenes PIK3CA and HRAS.

The associations between reduced OS and TERTp mutations and CDKN2A/B status remained significant after adjusting for Simpson resection grade. Our findings support using TERTp mutations and CDKN2A/B status for prognostication in grade 3 meningioma.

P1/2, N=96, Active, not recruiting, Washington University School of Medicine | Trial completion date: Apr 2025 --> Oct 2024

There is a positive significant correlation between early resectable stage in relation to positive P16 immunostaining, and the same was present between late nonresectable stage and negative P16 immunostaining (p = 0.000). The present study concluded that P16 positive immunostaining prevalence in cervical squamous cell carcinoma was 56.7% and its positive staining is highly correlated with early resectable clinically and radiologically disease stage.

CDKN2A deletion can be reliably detected with the TruSight Oncology 500 hybridization-capturebased platform and can be clinically validated through concordance analysis with an orthogonal testing platform. Further evaluation of the concordance of FISH-detected locus deletion homozygosity versus heterozygosity to copy number threshold is currently being evaluated.

The p16 was absent in all non-neoplastic and precursor lesions. Thus, it can provide essential information not only about HPV association but also on the prognostic implications for the patients.

P=N/A, N=532, Recruiting, Medical University of South Carolina | Not yet recruiting --> Recruiting

P1, N=42, Not yet recruiting, University of Chicago

P2, N=130, Not yet recruiting, Replimune Inc. | Initiation date: Sep 2023 --> Jan 2024

Of 104 vulvar cancer patients, prognostic factors that significantly correlated with worsening PFS were coexisting vulvar lesions, such as sclerosis and extramammary Paget's disease (p=0.008), positive lymphovascular invasion (LVSI) (p=0.011), positive pelvic or paraaortic node metastases (p=0.042), and positive p53 status (p=0.046). Tumor size over 4 cm in diameter was significantly associated with worsening OS (p=0.001). The median PFS was 26.3 months, and the median OS was 44.7 months.

P2, N=30, Not yet recruiting, IO Biotech | N=60 --> 30 | Trial completion date: Mar 2029 --> Aug 2028 | Trial primary completion date: Feb 2025 --> Sep 2025

P2, N=142, Completed, Radiation Therapy Oncology Group | Active, not recruiting --> Completed